[CAS NO. 500577-51-5] Cyclo (-RGDfK)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [500577-51-5]

Catalog

SLK-S7834

Brand

Selleck

CAS

500577-51-5

DESCRIPTION [500577-51-5]

Overview

MDL	MFCD20488083
Molecular Weight	717.69
Molecular Formula	C29H42F3N9O9
SMILES	O=C(O)C(F)(F)F.O=C(O)C[C@@H](C(N[C@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NC2)=O)=O)=O)=O)NC2=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.3934 mL	6.9668 mL	13.9336 mL
5 mM	0.2787 mL	1.3934 mL	2.7867 mL
10 mM	0.1393 mL	0.6967 mL	1.3934 mL
50 mM	0.0279 mL	0.1393 mL	0.2787 mL

Description

Cyclo (-RGDfK) is a potent and selective inhibitor.

Targets

αvβ3 integrin ^[1]

In vitro

The constant of affinity (K) of Cyclo (-RGDfK-) for purified integrin is 41.70 nM. Cyclo (-RGDfK) is reacting with HEK293(β3) cells moderately. Cyclo(-RGDfK-) modified micelles shows strong affinity to T-24 cells and strong inhibitory effect on the proliferation of T-24 cells.

In vivo

In athymic mice bearing α(v)β(3)-integrin-positive C6 gliomas, Cyclo (-RGDfK-) modification induces less tumor progression, less tumor metabolic activity, fewer intratumoral vessels.

References

[1] Dai XD, et al. Tetrahedron Letters. 2000, 41(33), 6295–6298.
[2] Sancey L, et al. Mol Ther. 2009, 17(5), 837-843.
[3] Jin ZH, et al. Mol Cancer. 2007, 6(41), 1-9.
[4] Zhou D, et al. J Control Release. 2013, 169(3), 204-210.
[5] Vilchis-Juárez A, et al. J Biomed Nanotechnol. 2014, 10(3), 393-404
[6] Haubner R, et al. J Nucl Med. 1999, 40(6), 1061-1071.